| ￥3500 | |
| Z05145-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 90% as determined by Bis-Tris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 66.32 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 67-70 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
CDH11/Cadherin 11, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 90%. »
| Target Background | CDH11 belongs to a group of transmembrane proteins that are principally located in adherens junctions. CDH11 mediates homophilic cell-to-cell adhesion, which may promote the development of cirrhosis. CDH11 expression was positively correlated with liver fibrosis in patients with cirrhosis, and could therefore be a prognostic factor in patients with liver fibrosis. |
| Synonyms | Cadherin-11;OSF-4;Osteoblast cadherin;OB-cadherin;CDH11;CAD11OSF-4; CDHOB;OB |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
